Pharmaceutical Executive-12-01-2010

Pharmaceutical Executive

After many years of building up an impressive resource base, the industry is finally ready to take advantage of the wave of enthusiasm and interest surounding pharma and biotech that is sweeping the nation

Pharmaceutical Executive

After many years of building up an impressive resource base, the industry is finally ready to take advantage of the wave of enthusiasm and interest surounding pharma and biotech that is sweeping the nation

Pharmaceutical Executive

Medigen shows how a collaborative approach can aide in tackling the biggest medical challenges

Pharmaceutical Executive
Feature

December 01, 2010

A small company shows how it can play a major role in a relatively short time frame

Pharmaceutical Executive

How to achieve distribution diversification in a small market

Pharmaceutical Executive

With a fiercely competitive spirit and grand ambitions that reach far beyond Taiwan, Standard is showing that it is far from the middle-of-the-road company its name implies

Pharmaceutical Executive

The simpler the explanation of a disorder and its treatment, the better able a patient is to take proper care of himself

Pharmaceutical Executive

Being strategic-and applying data tools effectively- will go along way in helping to produce analytics that drive sales

Pharmaceutical Executive
Features

December 01, 2010

Pharm Exec's Pipeline Report 2012

Pharmaceutical Executive
Features

December 01, 2010

Pharm Exec's Pipeline Report 2017

Pharmaceutical Executive
Columns

December 01, 2010

Healthcare marketing in today's post-recession economy is not about one-size-fits-all vehicles, but rather about bringing your prouct into consumers' lives in a series of personal, non-invasive ways

Columns
Pharmaceutical Executive

December 01, 2010

The new investigative journalism organization recently took an in-depth look at pharma with its "Dollars for Docs" report. In return, Pharm Exec takes a look back at ProPublica

Pharmaceutical Executive

Pharm Exec's Pipeline Report 2024

Pharmaceutical Executive
From the Editor

December 01, 2010

The end of anther year is an appropriate time to highlight the march of time-and the transitions that accompany it

Pharmaceutical Executive

Pharm Exec's Pipeline Report 2023

Pharmaceutical Executive
Columns

December 01, 2010

Stepped-up enforcement of the Foreign Corrupt Practices Act requires enhanced global coordination of compliance

Pharmaceutical Executive
Columns

December 01, 2010

Republican gains in Congress create uncertainty for health reform, drug regulation, and biomedical research

Pharmaceutical Executive

Pharm Exec's Pipeline Report 2020

Pharmaceutical Executive
Features

December 01, 2010

Pharm Exec's Pipeline Report 2011

Pharmaceutical Executive

Putting science front-and-center in the design of patient adherence programs can lead to a better understanding of the commitment required to get patients to take their medicine

Pharmaceutical Executive
Features

December 01, 2010

Pharm Exec's Pipeline Report 2013

Outgoing EMA Director Thomas Lonngren discusses a decade at the helm of Europe's top regulatory office

Pharmaceutical Executive
Features

December 01, 2010

Pharm Exec's Pipeline Report 2022

Pharmaceutical Executive
Features

December 01, 2010

Pharm Exec's Pipeline Report 2019

Pharmaceutical Executive

Pharm Exec's Pipeline Report 2021

Pharmaceutical Executive

42 of the best new drugs in development–or parked at the FDA

Pharmaceutical Executive
Features

December 01, 2010

Pharma sets the pace for China's ambitious new innovation agenda

Pharmaceutical Executive
Columns

December 01, 2010

The strict regulatory divide between market authorization and price reimbursement iscrumbling in the US. Is industry prepared to adapt or challenge?

Pharmaceutical Executive

Cegedim survey documents whether European industry is ready for the challenge of new compliance and disclosure risks on promotional spend

Pharmaceutical Executive

Pharm Exec's Pipeline Report 2016